Kimberly Duran
Pronouns: she/her
Research Mentor(s): Ulka Vaishampayan
Research Mentor School/College/Department: Internal Medicine, Hem/Oncology / Medicine
Program:
Authors:
Session: Session 2: 10:00 am – 10:50 am
Poster: 58
Abstract
Breast cancer is one of the leading causes of cancer death among women in the United States. The mammogram has been accepted as an early-stage breast cancer detector across the world. However, It is often an invasive and time-consuming process for patients. Furthermore, it lacks the flexibility to be easily utilized even in underdeveloped nations. The TriNetraTM-Breast test is a circulating tumor cell-based test and preliminary studies detected a high sensitivity rate for breast cancer detection. The purpose of this study is to test the performance of the Trinertra-Breast test as a reliable and safe early-stage breast cancer detector for women ages 40 and above in comparison to other cancer screeners such as mammograms. Eligible participants are 40 + years of age with no prior history of cancer and obtaining a mammogram or breast biopsy due to suspicious findings on mammography. All participants have to sign informed consent after a review of study design. Eligible and registered patients donate a blood sample. The mammogram/biopsy results are to be used to evaluate the clinical status of the participant, along with a follow-up every 6 months for one year. The testing of the blood sample is conducted by investigators blinded to the clinical information. The blood results will be correlated later with clinical data. Sensitivity, specificity, positive and negative predictive values will be determined. TriNetraTM-Breast has the potential of being established as a reliable breast cancer detection tool and may lead to an easier cancer screening option on a global scale.
